Washington, District of Columbia 2021-06-15 13:41:59 –
June 15, 2021
Federal agency that regulates drug prices and health insurance Are concerned The industry practice of using rebates to lower insurers’ drug costs has led to higher patient list prices and out-of-pocket costs.
To find out if patients were paying more for rebates to insurance companies, with or without insurance, researchers led by the University of Washington examined cost and price data for over 400 branded drugs. I did.The· Research Rebates were found to be associated with increased out-of-pocket costs for patients, averaging $ 6 for commercial insurance patients, $ 13 for Medicare patients, and $ 39 for uninsured patients.
“We know that as with rebates, list prices have risen very dramatically, but no one has looked at the link between rebates and out-of-pocket costs,” said the lead author of the study. .. Kayon, Affiliate Assistant Professor CHOICE Institute At the UW pharmacy. “Increased out-of-pocket costs are associated with rebates, but rebates also help keep premium costs down.”
As a result, Kaiser Permanente Bernard J. Tyson, an assistant professor at the School of Medicine, said, “The impact of pricing mechanisms on the most affected uninsured was not fully focused.” It states.
for A study presented at JAMA on June 14th, Researchers used data on 444 branded drugs, not generics, from national datasets, including federal government medical costs and drug prices from 2007 to 2018 Medical Expense Panel Survey And SSR health, A private company that collects and analyzes prescription drug price data.
Researchers point out that higher costs can affect patient health, as patients may take medication less often. As a result, emergency room use and hospitalization may increase. Those in the study who were not insured were in the worst health, and those with low incomes were less likely to take the prescribed medication when the cost increased.
“In addition, uninsured individuals are more likely to belong to racial minority groups, amplifying existing disparities in medical access,” the researchers wrote.
As a result, the authors suggest that future research and policy should focus on separating the list price from what patients pay for themselves, “especially for uninsured individuals.”
“The biggest point is to understand that rebates can reduce the cost of prescription medications for insurers and reduce premiums,” the co-authors said. Anirban BasooThe Stergachis family is the director of the CHOICE Institute and a professor of health economics at the UW School of Pharmacy. “It is unclear how much the discount will reduce premiums, but the out-of-pocket structure associated with this joint insurance and list price will help reduce the out-of-pocket costs for patients using treatment. It does not mean.”
Co-author Stacie Dusetzina of Vanderbilt University School of Medicine in Nashville, Tennessee. This study was partially supported by a grant from the Donahue Foundation’s Greater Value Portfolio.
Drug rebates for insurers tied to higher costs for patients, especially the uninsured Source link Drug rebates for insurers tied to higher costs for patients, especially the uninsured